▼Lurasidone (Latuda—Sunovion) is a new oral second-generation antipsychotic licensed for treating adults with schizophrenia. Although less likely to cause extrapyramidal adverse effects than first-generation antipsychotics, some second-generation antipsychotics cause weight gain that may increase the risk of diabetes, hypertension and raised lipid levels.1,2 Lurasidone is promoted as offering a balance between efficacy and tolerability, with reported negligible effects on weight and minimal effects on glucose and cholesterol.3 Here we review evidence for lurasidone's efficacy and safety, and consider how it compares with other antipsychotics.
Statistics from Altmetric.com
If you wish to reuse any or all of this article please use the link below which will take you to the Copyright Clearance Center’s RightsLink service. You will be able to get a quick price and instant permission to reuse the content in many different ways.